Overall Survival With Lutetium 177 May Be Impacted by Subsequent Therapies, Prognostic Risk Groups in mCRPC

Article

The CALGB prognostic risk group and subsequent life-prolonging therapies could potentially impact overall survival in patients with metastatic castration-resistant prostate cancer who are receiving lutetium 177.

Overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving Lutetium 177 (177Lu) shows correlation with Cancer and Leukemia Group B (CALGB) prognostic risk groups and receipt of subsequent FDA-approved life-prolonging therapies, according to a combined prognostic factor analysis.

The overall median OS observed with 177Lu was 20.7 months (95% CI, 17.4-24.0) in 125 patients with mCRPC who received treatment on sequential prospective clinical trials of the prostate-specific membrane antigen (PSMA)–targeted beta-emitting radionuclide. The median OS in those who received 177Lu-J591 (n = 76) was slightly longer, at 23.3 months (95% CI, 21.1-32.6). In those who received 177Lu-PSMA-617 (n = 49), the median OS was 16.7 months (95% CI, 10.9-20.7).

Factors linked with longer OS included CALGB prognostic score (28.1 months vs 16.9 months; P < .0001), circulating tumor cell (CTC) decline (24.9 months vs 19.2 months; P = .046), and receipt of subsequent therapy (28.1 months vs 14.8 months; P = .0002).

Moreover, higher PSMA PET standardized uptake value (SUV; imaging score 4 vs 0 to 3) was linked with prolonged OS (18 months vs 10 months; P = .015), and higher administered activity (22.1 months vs 18.6 months; P = .074) and DNA damage repair (DDR) alterations (33.9 months vs 20.6 months; P = .24) tended to be associated with longer OS.

“DDR mutations, higher administered radioactivity, higher PSMA PET SUV, and posttreatment [circulating tumor cell] count decline are promising biomarkers worthy of further exploration,” Scott Tagawa, MD, MS, FACP, study author, professor of medicine and urology at Weill Cornell Medicine, and an attending physician at NewYork-Presbyterian–Weill Cornell Medical Center, said in a poster presentation on the data.

PSMA-targeted radionuclide therapy represents a promising treatment for patients with advanced prostate cancer, Tagawa said. PSMA can be targeted using antibodies, such as J591, or small molecule ligands, like PSMA-617, labeled with 177Lu. However, optimal selection and effective biomarkers still need to be defined and established, Tagawa added.

To conduct the combined prognostic analysis presented during the meeting, investigators collected data from a total of 125 patients who received treatment with 177Lu on prospective PSMA-TRT clinical trials at a single institution between 2003 and 2020. To be included in the analysis, patients had to have completed treatment with the radionuclide therapy at least 1 year before the analysis.

Variables of interest included type of PSMA targeting, dose administered, comorbidities, CALGB prognostic risk group, PSMA imaging, CTC counts, known DDR alterations, and receipt of subsequent therapies. PSMA imaging was scored based on the maximum tumor uptake relative to the mean liver uptake on a scale that ranged from 0 to 4. Investigators utilized Cox regression analysis and the Kaplan-Meier method to examine the link between the variables and survival. The data cutoff for the combined analysis was March 2021.

Among the 125 patients included, the median PSA was 50.14 ng/dL (range, 0.66-2222.4) and the median age at treatment was 72 years (range, 48-93). Regarding Halabi risk category, 57.6% of patients had high risk, 37.6% had intermediate risk, and 4.8% had low risk. Additionally, 49.6% previously received taxane chemotherapy and 47.2% previously received abiraterone acetate (Zytiga)/enzalutamide (Erleada). Eighty percent of patients had metastasis in the lymph node, 24.8% in the liver, 24.8% in the lung, and 97.6% in the bone.

The median number of subsequent therapies received was 1 (range, 0-10), and these included abiraterone/enzalutamide (26.4%), docetaxel (32.8%), cabazitaxel (Jevtana; 18.4%), platinum chemotherapy (17.6%), radium-223 dichloride (Xofigo; 7.2%), sipuleucel-T (Provenge; 4.8%), and additional PSMA-TRT (11.2%).

Additional data from a multivariable analysis indicated that high Halabi risk group (HR, 1.78; 95% CI, 1.16-2.73; P = .009) and total number of subsequent therapies (HR, 0.79; 95% CI, 0.71-0.89; P < .001) retained their prognostic significance. Moreover, a trend for DDR mutations holding prognostic significance was observed (HR, 0.68; 95% CI, 0.34-1.36; P = .30).

These data were reported in September 2021 at the American Urological Association Annual Meeting.

Reference

Sun M, Thomas C, Ho B, et al. Long-term follow-up and prognostic factor analysis in men with metastatic castration-resistant prostate cancer (mCRPC) who receive prostate-specific membrane antigen (PSMA)-targeted lutetium-177 (177Lu). Presented at: 2021 American Urological Association Annual Meeting; September 10-13, 2021; virtual. Abstract MP24-05.

Related Videos
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Adverse effects associated with oral azacitidine in low- or intermediate-risk MDS are typically transient, according to Mikkael A. Sekeres, MD, MS.
Related Content